지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Weight loss via lifestyle modification remains the most efficient treatment for NAFLD. Weight loss and exercise are thecornerstones of therapy, but achieving long-term lifestyle modification is not free from difficulties. Pharmacologic therapy shouldbe considered for patients with NAFLD unable to achieve or maintain lifestyle-induced weight loss. Unfortunately, there is noapproved drug for NAFLD currently. Current treatment methods for NAFLD can be divided roughly into those methods that targetcomponents of metabolic syndrome using weight reduction and insulin sensitizers (pioglitazone) and those that use antioxidants(Vitamin E) to benefit the liver. Pioglitazone has been shown to improve steatosis, hepatocellular ballooning, and inflammation andalso to reduce the risk of fibrosis progression in several randomized-controlled trials (RCTs). In a large RCT, large doses of vitaminE improved all histological lesions except for fibrosis. Compared with a placebo, Metformin lowered ALT, but did not improveliver histology. Recently, novel anti-diabetic agents (GLP-1 analogues, DPP IV inhibitors) and probiotics that alter the gutmicrobiome were shown to mildly benefit ALT and liver histology. In this report, we systemically review current pharmacologictherapies and other promising agents that were not considered in the most recent guidelines for the treatment of NAFLD.
목차
등록된 정보가 없습니다.
참고문헌 (23)
참고문헌 신청
Aithal GP / 2008 / Randomized, placebo- controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis / Gastroenterology 138 : 1176 ~ 1184
Belfort R / 2006 / A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis / N Engl J Med 355 : 2297 ~ 2307
Bellentani S / 2008 / Fatty Liver Italian Network. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach / Hepatology 47 : 746 ~ 75
Bugianesi E / 2005 / A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease / Am J Gastroenterol 100 : 1082 ~ 1
Gadde KM / 2011 / Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQ
Belfort R / 2006 / A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis / N Engl J Med 355 : 2297 ~ 2307
Bellentani S / 2008 / Fatty Liver Italian Network. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach / Hepatology 47 : 746 ~ 75
Bugianesi E / 2005 / A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease / Am J Gastroenterol 100 : 1082 ~ 1
Gadde KM / 2011 / Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQ
이 논문의 저자 정보
최근 본 자료
댓글(0)
0